Pharmicell Co Ltd (XKRX:005690) Share Price

Company Profile

Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KOR
T: +82 234960114
http://www.pharmicell.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
161

Recommended

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

ChatGPT and large language models should be a tailwind for this company.

Simonelle Mody | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,006.40	19.00	-0.21%
CAC 40	8,157.82	69.50	-0.84%
DAX 40	24,128.98	26.47	-0.11%
Dow JONES (US)	49,171.54	138.78	-0.28%
FTSE 100	10,379.08	77.93	-0.75%
HKSE	25,978.07	62.87	0.24%
NASDAQ	24,806.45	367.95	1.51%
Nikkei 225	59,716.18	575.95	0.97%
NZX 50 Index	12,874.94	9.99	-0.08%
S&P 500	7,156.92	48.52	0.68%
S&P/ASX 200	8,786.50	12.10	-0.14%
SSE Composite Index	4,079.90	13.35	-0.33%